RBRuben Bouma

Ruben Bouma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruben Bouma has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Trends in incidence and prevalence of patients living long-term with de novo metastatic incurable cancer: a retrospective cohort study

    by Ruben Bouma, Olaf P. Geerse, Natasja J. H. Raijmakers, Heidi P. Fransen, Lia van Zuylen, Anna K. L. Reyners, Kristel van Asselt, Maatje D. A. van Gastel, Daan Brandenbarg, Mariken E. Stegmann

    Background Therapeutic advances have improved the survival of incurable cancer patients, creating a growing population living long-term with incurable cancer. However, little is known about their epidemiological characteristics. We aimed to examine trends in annual incidence and prevalence among patients living long-term with de novo metastatic incurable cancer in the Netherlands and to describe additional relevant sociodemographic and clinical characteristics among patients diagnosed in recent years. Methods A population-based, retrospective cohort study using data from the Netherlands Cancer Registry was performed. Adults (≥18 years) diagnosed with de novo metastatic solid tumors in 2000–2021 who survived ≥2 years after their diagnosis were included. Annual incidence, prevalence, key demographic, and tumor characteristics were calculated. Results Annual incident cases of patients living long-term with de novo metastatic incurable cancer increased from 1298 (2000) to 5398 (2021), representing 12.0–22.6% of incurable cancer diagnoses. In February 2024, at least 18,466 patients in the Netherlands were living long-term with de novo metastatic incurable cancer (1 per 1000 inhabitants). Mean age was 64 years (SD 12), 59.4% were male, and 55.8% (n = 10,310) were alive 2- < 5 years after diagnosis, 31.0% (n = 5721) 5- < 10 years, and 13.2% (n = 2435) ≥ 10 years. The most common tumor types were prostate (35.6%), lung (20.2%), breast (14.4%), and colorectal cancer (6.3%). Conclusion Substantial increases in the incidence and prevalence were identified, reflecting a shift toward prolonged survival within the incurable cancer population. Greater awareness and research are needed to inform care for this emerging group.

  • Open Access

    Defining patients living long-term with incurable cancer: A modified hybrid Delphi study

    by Ruben Bouma, Mariken E. Stegmann, Natasja J. H. Raijmakers, Lia van Zuylen, Anna K. L. Reyners, Kristel van Asselt, Maatje D. A. van Gastel, Daan Brandenbarg, Olaf P. Geerse

    Background: Therapeutic advances have significantly extended survival for certain groups of patients with incurable cancer, creating a growing population living long-term with incurable cancer. However, the absence of standardized definitions and terminology has contributed to limited recognition of this distinct group and their specific care needs. Aim: To achieve consensus on definitions and terminology for patients living long-term with incurable cancer by incorporating perspectives of patients, informal caregivers, healthcare professionals, and other relevant stakeholders. Design: A modified hybrid Delphi study, comprising focus groups and a three-round Delphi consensus process. Setting/participants: Three focus groups were conducted with patients ( n = 11), informal caregivers ( n = 4), and healthcare professionals ( n = 6). The multidisciplinary expert group comprised medical specialists ( n = 5), epidemiologists ( n = 3), and patient advocates ( n = 2). The Delphi study involved 78 panelists (73 unique respondents) divided into three subpanels: patients and informal caregivers ( n = 22), healthcare professionals ( n = 36), and other stakeholders ( n = 20). All participants were from the Netherlands. Results: We achieved 88% consensus on the terminology: Patients living long-term with incurable cancer. Consensus was reached on the definition (94%) for patients living for two or more years with: (1) incurable metastatic cancer, (2) incurable hematological malignancies, (3) incurable locally advanced cancer, or (4) patients with exceptionally long survival for their cancer type, despite not meeting the 2-year criterion. Conclusions: This modified hybrid Delphi study established the first consensus-based framework for patients living long-term with incurable cancer, providing essential groundwork for improved recognition and tailored care approaches for this population.